Literature DB >> 28991714

The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis.

Philippa Miller1, Andrew Soundy2.   

Abstract

AIM: The clinical aim was to provide up-to-date evidence-based recommendations for the treatment of MS-related fatigue (MSRF). The scientific aim was to prioritise topics for future randomised clinical trials with sufficient power.
METHODS: A systematic search of review based research that considered MSRF in adults (18years and over) was undertaken in May 2016. Data from reviews was extracted, critically appraised and synthesised using four specific techniques.
RESULTS: A total of 24 reviews were identified (17 non-pharmacological, 5 pharmacological, 2 combining both), which contained 339 studies on interventions deigned to improve MSRF. The methodological quality of the reviews was identified by an average AMSTAR score of 6.5 (SD=1.87: 95% CI=5.75-7.25). No pharmacological intervention had strong evidence for improving MSRF. Limited/conflicting evidence was found for Amantadine and Prokarin and potential benefits for Modafinil were identified. Pemoline and Carnitine contained unclear/no evidence for fatigue management. Non-pharmacological interventions produced mixed conclusions regarding the effectiveness of the intervention to improve MSRF. Education (energy conservation and fatigue management) and exercise had supporting evidence for reducing MSRF but mixed conclusions gathered from subtypes of exercise. Reviews considering psycho-behavioural interventions (CBT and mindfulness) had limited information considering effectiveness. Finally, a single intervention combining physical and cognitive strategies showed more promising results.
CONCLUSION: Further research into Pharmacological interventions for MSRF is required notably considering the potential of Modafinil. Yoga and energy conservation/fatigue management programs had strong evidence supporting use in management of MSRF. Due to the dissimilar interventions used in combined training the subtype of exercise cannot be recommended. Future research into Amantadine, psycho-behavioural interventions is vital to justify the current National Institute for Health and Care Excellence guidelines. The methodological quality of studies inhibited the ability of this review to provide other recommendations.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28991714     DOI: 10.1016/j.jns.2017.08.012

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  20 in total

1.  Characterizing fatigue phenotypes with other symptoms and clinically relevant outcomes among people with multiple sclerosis.

Authors:  Matthew Plow; Douglas D Gunzler; Julia H C Chang
Journal:  Qual Life Res       Date:  2022-08-18       Impact factor: 3.440

Review 2.  Brain Structural and Functional Alterations in Multiple Sclerosis-Related Fatigue: A Systematic Review.

Authors:  Chiara Barbi; Francesca Benedetta Pizzini; Stefano Tamburin; Alice Martini; Anna Pedrinolla; Fabio Giuseppe Laginestra; Gaia Giuriato; Camilla Martignon; Federico Schena; Massimo Venturelli
Journal:  Neurol Int       Date:  2022-06-08

3.  The Effect of Chronic Exercise on Energy and Fatigue States: A Systematic Review and Meta-Analysis of Randomized Trials.

Authors:  Carly L A Wender; Mika Manninen; Patrick J O'Connor
Journal:  Front Psychol       Date:  2022-06-03

4.  Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial.

Authors:  Farrah J Mateen; Andre C Vogel; Tamara B Kaplan; Gladia C Hotan; Sara J Grundy; Kathryn B Holroyd; Natalie Manalo; Matthew Stauder; Aleksandar Videnovic
Journal:  J Neurol       Date:  2020-04-24       Impact factor: 4.849

5.  Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigue.

Authors:  Magdalena Krbot Skorić; Luka Crnošija; Ivan Adamec; Barbara Barun; Tereza Gabelić; Tomislav Smoljo; Ivan Stanić; Tin Pavičić; Ivan Pavlović; Jelena Drulović; Tatjana Pekmezović; Mario Habek
Journal:  Clin Auton Res       Date:  2018-09-12       Impact factor: 4.435

6.  Symptom management of patients with multiple sclerosis in primary care: focus on overlooked symptoms.

Authors:  Athanasios Papathanasiou; Laura Saunders; Gillian Sare
Journal:  Br J Gen Pract       Date:  2021-02-25       Impact factor: 5.386

7.  The Efficacy of Psychological Interventions for Managing Fatigue in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Authors:  Aung Zaw Zaw Phyo; Thibaut Demaneuf; Alysha M De Livera; George A Jelinek; Chelsea R Brown; Claudia H Marck; Sandra L Neate; Keryn L Taylor; Taylor Mills; Emily O'Kearney; Amalia Karahalios; Tracey J Weiland
Journal:  Front Neurol       Date:  2018-04-04       Impact factor: 4.003

8.  The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases.

Authors:  Murray W Enns; Charles N Bernstein; Kristine Kroeker; Lesley Graff; John R Walker; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; John D Fisk; Ruth Ann Marrie
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

9.  Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis.

Authors:  Mojtaba Khazaei; Ashkan Karevan; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  Clin Transl Med       Date:  2019-07-01

Review 10.  Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis.

Authors:  Zina-Mary Manjaly; Neil A Harrison; Hugo D Critchley; Cao Tri Do; Gabor Stefanics; Nicole Wenderoth; Andreas Lutterotti; Alfred Müller; Klaas Enno Stephan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-01-25       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.